DOP2016000102A - (aza)piridopirazolopirimidinonas e indazolopirimidinonas y su uso - Google Patents
(aza)piridopirazolopirimidinonas e indazolopirimidinonas y su usoInfo
- Publication number
- DOP2016000102A DOP2016000102A DO2016000102A DO2016000102A DOP2016000102A DO P2016000102 A DOP2016000102 A DO P2016000102A DO 2016000102 A DO2016000102 A DO 2016000102A DO 2016000102 A DO2016000102 A DO 2016000102A DO P2016000102 A DOP2016000102 A DO P2016000102A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- aza
- bleeding
- hereditary
- piridopirazolopirimidinonas
- indazolopirimidinonas
- Prior art date
Links
- 230000000740 bleeding effect Effects 0.000 abstract 2
- 239000008280 blood Substances 0.000 abstract 2
- 210000004369 blood Anatomy 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 206010019860 Hereditary angioedema Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
- 201000004595 synovitis Diseases 0.000 abstract 1
- 238000002054 transplantation Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
LA PRESENTE SOLICITUD SE RELACIONA CON NUEVAS (AZA)PIRIDOPIRAZOLOPIRIMIDINONAS E INDAZOLOPIRIMIDINONAS SUSTITUIDAS, CON PROCESOS PARA SU PREPARACIÓN, EN DONDE LOS COMPUESTOS SE USAN SOLOS O EN COMBINACIONES EN UN MÉTODO PARA EL TRATAMIENTO Y/O PROFILAXIS DE ENFERMEDADES, EN PARTICULAR PARA EL TRATAMIENTO Y/O PROFILAXIS DE SANGRADO AGUDO Y RECURRENTE EN PACIENTES CON O SIN TRASTORNOS DE SANGRADO HEREDITARIOS O ADQUIRIDOS SUBYACENTES, EN DONDE EL SANGRADO ESTÁ ASOCIADO CON UNA ENFERMEDAD O INTERVENCIÓN MÉDICA QUE SE ELIGE DEL GRUPO QUE CONSISTE EN MENORRAGIA, HEMORRAGIA POSPARTO, CHOQUE HEMORRÁGICO, TRAUMA, CIRUGÍA, TRASPLANTE, INFARTO, ENFERMEDADES HEPÁTICAS, ANGIOEDEMA HEREDITARIO, SANGRADO DE NARIZ, Y SINOVITIS Y DAÑO DE CARTÍLAGO LUEGO DE HEMARTROSIS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13191642 | 2013-11-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2016000102A true DOP2016000102A (es) | 2016-06-30 |
Family
ID=49517406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2016000102A DOP2016000102A (es) | 2013-11-05 | 2016-05-05 | (aza)piridopirazolopirimidinonas e indazolopirimidinonas y su uso |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US9598417B2 (es) |
| EP (1) | EP3066100B1 (es) |
| JP (1) | JP6431061B2 (es) |
| KR (1) | KR102312780B1 (es) |
| CN (1) | CN105683194B (es) |
| AP (1) | AP2016009175A0 (es) |
| AR (1) | AR098292A1 (es) |
| AU (1) | AU2014345771B2 (es) |
| CA (1) | CA2929378C (es) |
| CL (1) | CL2016001076A1 (es) |
| CR (1) | CR20160332A (es) |
| CU (1) | CU24361B1 (es) |
| DO (1) | DOP2016000102A (es) |
| EA (1) | EA029373B1 (es) |
| ES (1) | ES2732305T3 (es) |
| GT (1) | GT201600084A (es) |
| IL (1) | IL244645B (es) |
| MA (1) | MA39018A1 (es) |
| MX (1) | MX370419B (es) |
| PE (1) | PE20160934A1 (es) |
| PH (1) | PH12016500828A1 (es) |
| SG (1) | SG11201602133RA (es) |
| TN (1) | TN2016000161A1 (es) |
| TW (1) | TWI657089B (es) |
| UA (1) | UA117504C2 (es) |
| UY (1) | UY35809A (es) |
| WO (1) | WO2015067549A1 (es) |
| ZA (1) | ZA201602311B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY35809A (es) * | 2013-11-05 | 2015-05-29 | Bayer Pharma AG | (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos |
| PE20170920A1 (es) * | 2014-11-03 | 2017-07-12 | Bayer Pharma AG | Piperidinilpirazolopirimidinonas y utilizacion de las mismas |
| WO2016173948A1 (en) * | 2015-04-30 | 2016-11-03 | Bayer Pharma Aktiengesellschaft | Indazolopyrimidinones as fibrinolysis inhibitors |
| WO2017007917A1 (en) * | 2015-07-07 | 2017-01-12 | Mast Therapeutics, Inc. | Polyoxyethylene/polyoxypropylene copolymers and fibrinolytic inhibitors, uses thereof and compositions |
| EP3318563A1 (en) | 2016-11-07 | 2018-05-09 | Sanofi | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders |
| CN110590673A (zh) * | 2019-09-02 | 2019-12-20 | 南通大学 | 一种4-氯-7-甲基-1h-吲唑及其化学合成方法 |
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| US11654057B2 (en) | 2020-04-09 | 2023-05-23 | Bio 54, Llc | Devices for bleeding reduction and methods of making and using the same |
| TWI803177B (zh) * | 2021-02-05 | 2023-05-21 | 大陸商賽諾哈勃藥業（成都）有限公司 | 一種纖維蛋白溶酶抑制劑、其製備方法及應用 |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| CN117500799A (zh) | 2021-06-09 | 2024-02-02 | 伊莱利利公司 | 作为kras g12d抑制剂的取代的稠合吖嗪 |
| US11642324B1 (en) | 2022-03-01 | 2023-05-09 | Bio 54, Llc | Topical tranexamic acid compositions and methods of use thereof |
| AU2023251136A1 (en) | 2022-04-05 | 2024-10-17 | Bayer Aktiengesellschaft | Inhibitors of chymase for use in the selective resolution of thrombi in thrombotic or thromboembolic disorders |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2192559A5 (en) * | 1972-07-17 | 1974-02-08 | Ugine Kuhlmann | Pyrimidino (1,2-b) indazole derivs - inters for dyes and pharmaceuticals, from 3-aminoindazoles and beta-ketone derivs |
| WO2006023001A1 (en) | 2004-07-30 | 2006-03-02 | Xanodyne Pharmaceuticals, Inc. | Tranexamic acid formulations |
| AR059224A1 (es) * | 2006-01-31 | 2008-03-19 | Jerini Ag | Compuestos para la inhibicion de integrinas y uso de estas |
| KR101673886B1 (ko) * | 2008-06-06 | 2016-11-08 | 사노피 | ＴＡＦＩａ의 억제제로서의 마크로사이클릭 우레아 및 술파미드 유도체 |
| US8691825B2 (en) | 2009-04-01 | 2014-04-08 | Merck Sharp & Dohme Corp. | Inhibitors of AKT activity |
| CN102459246B (zh) | 2009-04-07 | 2014-05-07 | 阿斯利康(瑞典)有限公司 | 作为治疗剂的异噁唑-3(2h)-酮类似物 |
| WO2012047156A1 (en) * | 2010-10-04 | 2012-04-12 | Astrazeneca Ab | Isoxazol-3(2h)-one analogs as plasminogen inhibitors and their use in the treatment of fibrinolysis related diseases |
| NZ610315A (en) * | 2010-11-15 | 2015-08-28 | Univ Leuven Kath | Antiviral condensed heterocyclic compounds |
| WO2012082947A1 (en) * | 2010-12-16 | 2012-06-21 | Irm Llc | Compounds and compositions as tgr5 agonists |
| CN103370321B (zh) * | 2010-12-16 | 2015-07-29 | 拜耳知识产权有限责任公司 | 取代的嘧啶并[1,2-b]吲唑及其作为PI3K/AKT途径的调节剂的用途 |
| UY35809A (es) * | 2013-11-05 | 2015-05-29 | Bayer Pharma AG | (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos |
| WO2016173948A1 (en) * | 2015-04-30 | 2016-11-03 | Bayer Pharma Aktiengesellschaft | Indazolopyrimidinones as fibrinolysis inhibitors |
-
2014
- 2014-10-31 UY UY0001035809A patent/UY35809A/es not_active Application Discontinuation
- 2014-11-03 EP EP14793523.3A patent/EP3066100B1/en active Active
- 2014-11-03 WO PCT/EP2014/073529 patent/WO2015067549A1/en not_active Ceased
- 2014-11-03 AP AP2016009175A patent/AP2016009175A0/en unknown
- 2014-11-03 EA EA201690935A patent/EA029373B1/ru not_active IP Right Cessation
- 2014-11-03 ES ES14793523T patent/ES2732305T3/es active Active
- 2014-11-03 SG SG11201602133RA patent/SG11201602133RA/en unknown
- 2014-11-03 TW TW103137976A patent/TWI657089B/zh not_active IP Right Cessation
- 2014-11-03 PE PE2016000586A patent/PE20160934A1/es unknown
- 2014-11-03 MX MX2016005969A patent/MX370419B/es active IP Right Grant
- 2014-11-03 MA MA39018A patent/MA39018A1/fr unknown
- 2014-11-03 AU AU2014345771A patent/AU2014345771B2/en not_active Ceased
- 2014-11-03 CR CR20160332A patent/CR20160332A/es unknown
- 2014-11-03 CN CN201480060660.7A patent/CN105683194B/zh not_active Expired - Fee Related
- 2014-11-03 UA UAA201605980A patent/UA117504C2/uk unknown
- 2014-11-03 TN TN2016000161A patent/TN2016000161A1/en unknown
- 2014-11-03 JP JP2016527398A patent/JP6431061B2/ja not_active Expired - Fee Related
- 2014-11-03 CA CA2929378A patent/CA2929378C/en not_active Expired - Fee Related
- 2014-11-03 CU CU2016000062A patent/CU24361B1/es unknown
- 2014-11-03 KR KR1020167014622A patent/KR102312780B1/ko not_active Expired - Fee Related
- 2014-11-04 AR ARP140104130A patent/AR098292A1/es not_active Application Discontinuation
- 2014-11-05 US US14/533,915 patent/US9598417B2/en not_active Expired - Fee Related
-
2016
- 2016-03-17 IL IL244645A patent/IL244645B/en active IP Right Grant
- 2016-04-06 ZA ZA2016/02311A patent/ZA201602311B/en unknown
- 2016-05-04 PH PH12016500828A patent/PH12016500828A1/en unknown
- 2016-05-05 GT GT201600084A patent/GT201600084A/es unknown
- 2016-05-05 DO DO2016000102A patent/DOP2016000102A/es unknown
- 2016-05-05 CL CL2016001076A patent/CL2016001076A1/es unknown
-
2017
- 2017-01-26 US US15/416,651 patent/US10098883B2/en active Active
-
2018
- 2018-08-10 US US16/101,250 patent/US10668071B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GT201600084A (es) | (aza) piridopirazolopirimidinonas e indazolopirimidinonas y su uso | |
| MX2023000796A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
| IL262591A (en) | Methods for treating patients with familial hypercholesterolemia | |
| EA201890725A1 (ru) | Агонисты фарнезоидного х-рецептора и их применение | |
| BR112015009948A8 (pt) | Antagonistas de ativina-actrii, usos dos mesmos para tratamento de doenças ósseas e outros distúrbios e método para monitorar a eficácia do tratamento ou prevenção de uma doença óssea e outros distúrbios | |
| CO2017004715A2 (es) | Métodos y formulaciones para tratar enfermedades vasculares de los ojos | |
| MX2015009104A (es) | Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares. | |
| MX2020009602A (es) | Formulaciones de pulverizacion de epinefrina. | |
| CR20200334A (es) | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas | |
| JOP20200231B1 (ar) | ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها | |
| CR11731A (es) | Composiciones y procedimientos para su preparación y uso | |
| MX383715B (es) | Formas sólidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y usos de las mismas. | |
| MX2014008156A (es) | Metodos de tratamiento de sintomas conductuales de trastornos neurologicos y trastornos mentales. | |
| AR092899A1 (es) | Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion | |
| BR112018005905A2 (pt) | ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto? | |
| MX2022014792A (es) | Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican. | |
| EA201692402A1 (ru) | Лекарственные формы для местного применения и их использование | |
| BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
| MX2015012315A (es) | Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica. | |
| MX2019007555A (es) | Uso de bacterias de acido láctico para tratar o prevenir la diabetes mellitus gestacional. | |
| BR112017020013A2 (pt) | método para preparação de um substituto da pele, substituto da pele, substituto dérmico, enxerto, enxerto para uso, e kit para implementação do método | |
| BR112018008769A2 (pt) | formulações farmacêuticas, formulações líquidas aquosa reconstituída e liofilizada, seringa, método de fabricação de uma formulação farmacêutica, método para tratamento de uma doença e uso de uma formulação reconstruída | |
| UY36385A (es) | Piperidinilpirazolopirimidinonas y utilización de las mismas | |
| MX2018002298A (es) | Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos. | |
| EA201500232A1 (ru) | Три(гетеро)арилпиразолы и их применение |